Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Orgenesis stock

ORGS
US68619K2042
A2H7XQ

Price

1.20
Today +/-
-0.03
Today %
-2.48 %
P

Orgenesis stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Orgenesis stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Orgenesis stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Orgenesis stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Orgenesis's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Orgenesis Stock Price History

DateOrgenesis Price
10/31/20241.20 undefined
10/30/20241.23 undefined
10/29/20241.17 undefined
10/28/20241.23 undefined
10/25/20241.20 undefined
10/24/20241.19 undefined
10/23/20241.15 undefined
10/22/20241.22 undefined
10/21/20241.53 undefined
10/18/20242.11 undefined
10/17/20243.24 undefined
10/16/20243.39 undefined
10/15/20242.90 undefined
10/14/20243.21 undefined
10/11/20243.75 undefined
10/10/20243.82 undefined
10/9/20243.94 undefined
10/8/20243.98 undefined
10/7/20243.83 undefined

Orgenesis Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Orgenesis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Orgenesis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Orgenesis’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Orgenesis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Orgenesis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Orgenesis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Orgenesis’s growth potential.

Orgenesis Revenue, EBIT and net profit per share

DateOrgenesis RevenueOrgenesis EBITOrgenesis Net Income
2025e74.24 M undefined13.55 M undefined2.09 M undefined
2024e71.71 M undefined16.52 M undefined2.97 M undefined
2023530,000 undefined-52.2 M undefined-55.36 M undefined
202236.03 M undefined-7.66 M undefined-14.89 M undefined
202135.5 M undefined-16.8 M undefined-18.05 M undefined
20207.65 M undefined-95.78 M undefined1.11 M undefined
20193.9 M undefined-21.98 M undefined-24.12 M undefined
201818.66 M undefined-13.92 M undefined-18.29 M undefined
201710.09 M undefined-10.02 M undefined-12.37 M undefined
20166.4 M undefined-11.28 M undefined-11.11 M undefined
20152.97 M undefined-7.21 M undefined-4.46 M undefined
20140 undefined-5.51 M undefined-5.5 M undefined
20130 undefined-5.46 M undefined-5.54 M undefined
20120 undefined-4.99 M undefined-5 M undefined
20110 undefined-70,000 undefined-70,000 undefined
20100 undefined-20,000 undefined-40,000 undefined
20090 undefined-30,000 undefined-30,000 undefined
20080 undefined0 undefined0 undefined

Orgenesis Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e
000000026101837353607174
--------200.0066.6780.00-83.33133.33400.002.86--4.23
---------16.6730.0038.89---94.44---
00000000-13700034-500
0000-4-5-5-7-11-10-13-21-95-16-7-521613
--------350.00-183.33-100.00-72.22-700.00-1,357.14-45.71-19.44-22.5417.57
0000-5-5-5-4-11-12-18-241-18-14-5522
--------20.00175.009.0950.0033.33-104.17-1,900.00-22.22292.86-103.64-
0.190.190.196.714.524.214.514.658.529.6813.3715.9121.3224.2725.129.0100
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Orgenesis Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Orgenesis is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2008200920102011201220132014201520162017201820192020202120222023
                               
0.060.02000.010.061.314.170.893.5214.610.1144.925.475.310.84
00000001.171.232.033.231.833.0915.2536.180.09
00000001.450.910.187.040.210.163.232.690.46
00000000.30.40.731.660.140.190.120.120.03
00000.030.040.11.120.780.841.5276.071.721.692.022.66
0.060.02000.040.11.418.214.217.328.0678.3650.0825.7646.324.08
00000.010.010.014.34.575.112.463.034.5511.2925.141.83
0000000001.32000.180.150.140.01
00000000001.012.6201.2500
00.020000016.6515.0515.0516.643.3513.0211.829.697.38
00000009.549.5810.6815.274.818.758.48.191.21
0000000.010.060.080.420.440.331.121.171.460.06
00.02000.010.010.0230.5529.2832.5745.8214.1427.6234.0844.6210.48
0.060.04000.050.111.4338.7633.4939.8773.8892.577.759.8490.9414.55
                               
0000.0100.010.0121.4600000000
0.050.050.050.054.858.6413.2115.4845.4556.8290.694.69140.4145.92150.36156.84
0-0.03-0.07-0.14-5.14-10.67-16.18-20.64-31.75-44.12-65.16-89.43-88.32-106.37-121.26-176.62
000000-0.02-1.29-1.211.430.670.210.750.21-0.270.07
0000000000000000
0.050.02-0.02-0.08-0.29-2.02-2.9815.0112.4914.1326.115.4752.8339.7628.83-19.72
000.010.040.140.141.083.484.553.914.585.558.655.244.436.58
0000.010.150.5412.162.894.44.553.642.742.874.983.51
0000.040.040.040.133.11.575.456.7832.430.761.351.942.97
000000.262.453.020.020000000.65
00000004.725.473.161.250.814.145.94.562.69
000.010.090.330.984.6616.4814.516.9217.1642.4316.2915.3615.9116.41
00000002.544.354.533.5112.147.264.913.4418.97
00000003.331.860.691.660.060000
000001.160.561.390.280.010.580.831.410.952.310.16
000001.160.567.266.495.235.7513.038.675.8515.7519.13
000.010.090.332.145.2223.7420.9922.1522.9155.4624.9621.2131.6635.54
0.050.02-0.010.010.040.122.2438.7533.4836.2849.0260.9377.7960.9760.4915.82
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Orgenesis provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Orgenesis's financial health and stability.

Assets

Orgenesis's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Orgenesis must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Orgenesis after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Orgenesis's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2008200920102011201220132014201520162017201820182019202020212022
0000-5-5-5-4-9-12-19-2-260-18-12
0000000122203111
00000000-1,000-1,0001,00000-1,00000
0000000122-402-1-15-19
0000333-114305-7645
0000000000000000
0000000000000000
0000-1-1-1-2-3-3-15-1-13-78-26-24
00000000-10-50-12-1-7-12
00000000-1-3-60-13105-12-14
000000000-200-1107-4-1
0000000000000000
00000002001010-2-116
00001104151700802
0000122628350245039
0000001002160130020
0000000000000000
00000012-3212-1-233-390
0-0.04-0.010-1.06-2-1.43-3.69-5.21-4.81-21.24-1.62-25.35-79.58-34.74-37.34
0000000000000000

Orgenesis stock margins

The Orgenesis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Orgenesis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Orgenesis.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Orgenesis's sales revenue. A higher gross margin percentage indicates that the Orgenesis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Orgenesis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Orgenesis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Orgenesis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Orgenesis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Orgenesis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Orgenesis Margin History

Orgenesis Gross marginOrgenesis Profit marginOrgenesis EBIT marginOrgenesis Profit margin
2025e-1,080.19 %18.25 %2.82 %
2024e-1,080.19 %23.04 %4.14 %
2023-1,080.19 %-9,849.62 %-10,445.47 %
202295.45 %-21.26 %-41.33 %
2021-1,080.19 %-47.32 %-50.85 %
2020-1,080.19 %-1,252.03 %14.51 %
2019-1,080.19 %-563.59 %-618.46 %
201841.96 %-74.6 %-98.02 %
201732.51 %-99.31 %-122.6 %
2016-19.69 %-176.25 %-173.59 %
2015-30.64 %-242.76 %-150.17 %
2014-1,080.19 %0 %0 %
2013-1,080.19 %0 %0 %
2012-1,080.19 %0 %0 %
2011-1,080.19 %0 %0 %
2010-1,080.19 %0 %0 %
2009-1,080.19 %0 %0 %
2008-1,080.19 %0 %0 %

Orgenesis Stock Sales Revenue, EBIT, Earnings per Share

The Orgenesis earnings per share therefore indicates how much revenue Orgenesis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Orgenesis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Orgenesis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Orgenesis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Orgenesis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Orgenesis Revenue, EBIT and net profit per share

DateOrgenesis Sales per ShareOrgenesis EBIT per shareOrgenesis Earnings per Share
2025e15.56 undefined0 undefined0.44 undefined
2024e15.03 undefined0 undefined0.62 undefined
20230.02 undefined-1.8 undefined-1.91 undefined
20221.44 undefined-0.31 undefined-0.59 undefined
20211.46 undefined-0.69 undefined-0.74 undefined
20200.36 undefined-4.49 undefined0.05 undefined
20190.25 undefined-1.38 undefined-1.52 undefined
20181.4 undefined-1.04 undefined-1.37 undefined
20171.04 undefined-1.04 undefined-1.28 undefined
20160.75 undefined-1.32 undefined-1.3 undefined
20150.64 undefined-1.55 undefined-0.96 undefined
20140 undefined-1.22 undefined-1.22 undefined
20130 undefined-1.3 undefined-1.32 undefined
20120 undefined-1.1 undefined-1.11 undefined
20110 undefined-0.01 undefined-0.01 undefined
20100 undefined-0.11 undefined-0.21 undefined
20090 undefined-0.16 undefined-0.16 undefined
20080 undefined0 undefined0 undefined

Orgenesis business model

Orgenesis Inc is a company specializing in the development of therapies for the treatment of diabetes and other diseases. The company was founded in 2008 to advance research on new therapy approaches for diabetes treatment. Its business model is based on the development of cell therapy technologies to treat patients with diabetes. The company focuses on developing therapies that use human cells to regulate the body's immune system and improve insulin production. Orgenesis Inc also offers consulting services to help other companies develop similar technologies. The company's goal is to provide technology and know-how to drive industrial progress and help people worldwide. Orgenesis Inc is divided into several areas, including biotherapeutics, where it researches and develops therapeutic cell therapies for diabetes and other chronic diseases. It also operates in the engineering services sector, assisting with the design, construction, and development of other therapies and medical devices. The company also distributes products for monitoring diabetes in patients, such as innovative devices that monitor blood glucose and other important parameters, triggering alarms when certain thresholds are exceeded. In summary, Orgenesis Inc is a leading company in the research and development of cell therapy technologies in the field of diabetes and autoimmune therapy. It engages in a wide range of activities, from consulting services to engineering tasks and marketing its own products. This "closed loop" approach of research, development, and marketing has made Orgenesis Inc an innovative company that plays a significant role in the global healthcare industry. Orgenesis is one of the most popular companies on Eulerpool.com.

Orgenesis Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Orgenesis Revenue by Segment

Segmente2023
Revenue from grants-
Cell manufacturing services-
Cell process development services-
This member stands for POC development services-
Tech transfer services-
Cell Process Development Services And Hospital Services515,000 USD
License Fees15,000 USD
Revenue from grants-
Therapies515,000 USD
Octomera68,000 USD
Eliminations-53,000 USD

Orgenesis SWOT Analysis

Strengths

1. Strong R&D capabilities, enabling development of innovative medical solutions.

2. Well-established partnerships with leading pharmaceutical companies.

3. Robust intellectual property portfolio, providing a competitive advantage.

Weaknesses

1. Limited market presence in certain regions, hindering global market expansion.

2. Relatively small size compared to major competitors, resulting in resource constraints.

3. High reliance on a single product line or technology, increasing vulnerability to market fluctuations.

Opportunities

1. Growing demand for personalized medicine, aligning with Orgenesis' expertise in cell therapies.

2. Emerging markets present untapped opportunities for expansion and revenue growth.

3. Increasing public awareness and support for regenerative medicine, facilitating market acceptance.

Threats

1. Stringent regulatory requirements in the healthcare industry, potentially delaying product approvals.

2. Intense competition from established players and new entrants in the market.

3. Economic downturns or market disruptions may impact healthcare spending and investment.

Orgenesis Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Orgenesis historical P/E ratio, EBIT multiple, and P/S ratio

Orgenesis shares outstanding

The number of shares was Orgenesis in 2023 — This indicates how many shares 29.008 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Orgenesis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Orgenesis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Orgenesis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Orgenesis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Orgenesis stock splits

In Orgenesis's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Orgenesis.

Orgenesis latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20231.02 -4.3  (-521.57 %)2023 Q3
6/30/20230.61 -1.5  (-345.1 %)2023 Q2
3/31/20230.51 -1.7  (-433.33 %)2023 Q1
12/31/20220 -1.6  (0 %)2022 Q4
9/30/2022-0.2 -0.5  (-145.1 %)2022 Q3
6/30/2022-0.2 -2.2  (-978.43 %)2022 Q2
3/31/2022-0.41 -1.6  (-292.16 %)2022 Q1
12/31/2021-0.61 -2.1  (-243.14 %)2021 Q4
9/30/2021-0.31 -4.2  (-1,272.55 %)2021 Q3
6/30/2021-2.35 -1.1  (53.11 %)2021 Q2
1
2

Eulerpool ESG Scorecard© for the Orgenesis stock

Eulerpool World ESG Rating (EESG©)

33/ 100

🌱 Environment

36

👫 Social

39

🏛️ Governance

24

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Orgenesis shareholders

%
Name
Stocks
Change
Date
10.71300 % Safier (Jacob)511,010311,0104/23/2024
6.26415 % New Dimensions Trading, Ltd.298,80025,31412/31/2023
3.40331 % NewTech Investment Holdings, LLC162,338162,3381/10/2023
1.90828 % The Vanguard Group, Inc.91,025-1,4866/30/2024
1.33069 % Knoll Capital Management, LLC63,47406/30/2024
0.59346 % Geode Capital Management, L.L.C.28,308-4886/30/2024
0.58321 % Caplan (Vered)27,81904/23/2024
0.16537 % State Street Global Advisors (US)7,8881,1226/30/2024
0.16440 % BlackRock Institutional Trust Company, N.A.7,842-4,2776/30/2024
0.13270 % Adler (Yaron)6,33004/23/2024
1
2
3
4
...
5

Orgenesis Executives and Management Board

Ms. Vered Caplan(54)
Orgenesis Chairperson of the Board of Directors, Chief Executive Officer (since 2012)
Compensation 443,909
Dr. David Sidransky(63)
Orgenesis Independent Director
Compensation 129,165
Mr. Guy Yachin(55)
Orgenesis Independent Director
Compensation 123,161
Mr. Ashish Nanda(58)
Orgenesis Independent Director
Compensation 83,729
Mr. Yaron Adler(51)
Orgenesis Independent Director
Compensation 77,725
1
2

Orgenesis Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
KinerjaPay Stock
KinerjaPay
SupplierCustomer0,260,010,04-0,080,71
Leidos Stock
Leidos
SupplierCustomer-0,060,350,690,340,220,04
HemoGenyx Pharmaceuticals Stock
HemoGenyx Pharmaceuticals
SupplierCustomer-0,600,590,34-0,220,710,54
1

Most common questions regarding Orgenesis

What values and corporate philosophy does Orgenesis represent?

Orgenesis Inc is a company driven by values and a corporate philosophy focused on advancing cell and gene therapy. They are committed to improving patient outcomes through innovative technologies and solutions. With a patient-centric approach, Orgenesis aims to transform the traditional treatment methods by developing personalized therapies that provide long-term benefits. By collaborating with leading experts in the field, they strive to accelerate the development of breakthrough treatments and enhance the accessibility of cell therapy. As an organization, Orgenesis promotes transparency, integrity, and responsible business practices. Their commitment to scientific excellence and patient well-being sets them apart in the industry.

In which countries and regions is Orgenesis primarily present?

Orgenesis Inc is primarily present in multiple countries and regions worldwide. The company has established a significant presence in the United States, Belgium, Israel, China, and South Korea. With its global expansion efforts, Orgenesis Inc aims to leverage local resources and partnerships to enhance its presence and capture opportunities in key international markets. The company's presence across these countries and regions reflects its commitment to advancing cell and gene therapies, as well as its strategic focus on growing its business globally.

What significant milestones has the company Orgenesis achieved?

Orgenesis Inc has achieved several significant milestones in its history. One notable achievement for the company was the development of its breakthrough therapeutic platform, which enables the conversion of liver cells into fully-functional, insulin-producing cells for the treatment of diabetes. This innovative technology has shown promising results in both pre-clinical and clinical studies, positioning Orgenesis Inc as a leader in the field of regenerative medicine. Additionally, the company has successfully entered into strategic partnerships and collaborations, strengthening its global presence and opening up new avenues for growth and development. These milestones highlight Orgenesis Inc's commitment to revolutionizing healthcare through cutting-edge solutions and strategic alliances in the biotech industry.

What is the history and background of the company Orgenesis?

Orgenesis Inc, based in Germantown, Maryland, is a leading biotechnology company focused on the development and commercialization of therapeutic products and technologies for advanced cell and gene therapies. Founded in 2008, the company has a rich history in the field of regenerative medicine. Orgenesis specializes in the development of autologous cell-based therapies, which involve using a patient's own cells to create personalized treatments for a range of diseases, including diabetes and liver diseases. With a strong commitment to innovation and collaboration, Orgenesis continues to make significant strides in advancing the field of regenerative medicine and improving patients' lives worldwide.

Who are the main competitors of Orgenesis in the market?

Orgenesis Inc faces competition from various companies in the market. Some of the main competitors include Tissue Regenix Group, Medtronic plc, Organogenesis Holdings Inc, Integra LifeSciences Holdings Corporation, and Vericel Corporation.

In which industries is Orgenesis primarily active?

Orgenesis Inc is primarily active in the biotechnology and life sciences industry.

What is the business model of Orgenesis?

Orgenesis Inc operates with a unique business model focused on advanced cell therapy development and transformative regenerative medicine. The company specializes in developing and manufacturing innovative, autologous cell therapies to address unmet medical needs, particularly in the field of diabetes. By leveraging its proprietary technology platforms, Orgenesis provides personalized medicine solutions that involve collecting and utilizing a patient's own cells for therapeutic purposes. This approach allows for more effective and safer treatments, leading to improved patient outcomes. Overall, Orgenesis is dedicated to revolutionizing the healthcare industry by harnessing the potential of regenerative medicine and advancing personalized cell therapies.

What is the P/E ratio of Orgenesis 2024?

The Orgenesis P/E ratio is 11.68.

What is the P/S ratio of Orgenesis 2024?

The Orgenesis P/S ratio is 0.48.

What is the Quality Investing of Orgenesis?

The Quality Investing for Orgenesis is 6/10.

What is the revenue of Orgenesis 2024?

The expected Orgenesis revenue is 71.71 M USD.

How high is the profit of Orgenesis 2024?

The expected Orgenesis profit is 2.97 M USD.

What is the business model of Orgenesis

Orgenesis Inc is a global biotechnology company that focuses on the development and commercialization of drugs for the treatment of diabetes and other metabolic diseases. The company operates through various divisions, including the hearing aid division, the cell therapy division, and the pharmaceutical division. The hearing aid division of the company focuses on the development, manufacturing, and marketing of hearing aids that help individuals with hearing loss. The hearing aids contain the latest technologies to improve sound quality and minimize background noise. The company offers a wide range of hearing aids that meet the different needs of its customers. In the cell therapy division, Orgenesis develops and produces cells for the regenerative medicine industry that can be used to treat various diseases such as type 1 diabetes, liver and lung diseases, and cancer. The company uses its proprietary platform technology to transform stem cells into specific, differentiated cell types that can contribute to the regeneration of affected tissues in the body. The pharmaceutical division of the company focuses on the development and commercialization of drugs for the treatment of diabetes and other metabolic diseases. Orgenesis has developed a platform technology that allows for the conversion of human cells into insulin-producing cells that help the body regulate its blood sugar levels. The company has also developed a technology for the production of subcutaneous insulins specifically designed for patients with type 1 and type 2 diabetes. Through its various divisions, Orgenesis Inc offers a wide range of products and services tailored to the needs of its customers. The company relies on a comprehensive research and development strategy to develop innovative technologies and solutions for the treatment of diabetes and other diseases. Orgenesis Inc pursues a partnership-based business model to expand its product portfolio and accelerate growth. The company collaborates with leading players in the regenerative medicine and pharmaceutical industries to market its products and technologies on a global scale. In collaboration with the University of Louisville in Kentucky, Orgenesis has established its own cadaver pancreas collection to research new approaches to the production of subcutaneous insulins. In March 2020, the company committed to a strategic focus on Advanced Therapy Medicinal Products (ATMP). The ATMP portfolio innovation is intended to be achieved through the company's acquisition of MaSTherCell in 2019, a therapist-led company specializing in the development of cell therapies from the research pipeline to the commercialization of drugs. Orgenesis' primary approach is to offer its customers high-quality, safe, and effective products that bring value to their lives. The company strives to be a leader in the biotechnology industry by developing innovative products and technologies that improve the quality of life for patients worldwide.

What is the Orgenesis dividend?

Orgenesis pays a dividend of 0 USD distributed over payouts per year.

How often does Orgenesis pay dividends?

The dividend cannot currently be calculated for Orgenesis or the company does not pay out a dividend.

What is the Orgenesis ISIN?

The ISIN of Orgenesis is US68619K2042.

What is the Orgenesis WKN?

The WKN of Orgenesis is A2H7XQ.

What is the Orgenesis ticker?

The ticker of Orgenesis is ORGS.

How much dividend does Orgenesis pay?

Over the past 12 months, Orgenesis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orgenesis is expected to pay a dividend of 0 USD.

What is the dividend yield of Orgenesis?

The current dividend yield of Orgenesis is .

When does Orgenesis pay dividends?

Orgenesis pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orgenesis?

Orgenesis paid dividends every year for the past 0 years.

What is the dividend of Orgenesis?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orgenesis located?

Orgenesis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orgenesis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orgenesis from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Orgenesis pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Orgenesis in the year 2023?

In the year 2023, Orgenesis distributed 0 USD as dividends.

In which currency does Orgenesis pay out the dividend?

The dividends of Orgenesis are distributed in USD.

All fundamentals about Orgenesis

Our stock analysis for Orgenesis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orgenesis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.